Last reviewed · How we verify
Baxter International — Portfolio Competitive Intelligence Brief
BAX (NYSE)
25 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Treanda | BENDAMUSTINE | marketed | Alkylating Drug | Histone deacetylase 6 | Oncology | 2008-01-01 |
| Cubicin | Daptomycin | marketed | lipopeptide antibacterial | Metabolic | 2003-01-01 | |
| Maxipime | Cefepime Hydrochloride | marketed | Cephalosporin | Bacterial cell wall peptidoglycan | Infectious Disease | 1996-01-01 |
| Maxipime | CEFEPIME | marketed | Cephalosporin Antibacterial | Infectious Disease | 1996-01-01 | |
| Suprane | DESFLURANE | marketed | General Anesthetic [EPC] | GABA-A receptor; anion channel | Neuroscience | 1992-01-01 |
| Ifex | IFOSFAMIDE | marketed | Alkylating Drug [EPC] | Oncology | 1988-01-01 | |
| Mesnex | MESNA | marketed | mesna | Oncology | 1988-01-01 | |
| Renacidin | CITRIC ACID | marketed | Anti-coagulant | Neuroscience | 1982-01-01 | |
| Prepopik | MAGNESIUM OXIDE | marketed | magnesium oxide | Gastroenterology | 1982-01-01 | |
| Cromosan | MAGNESIUM ACETATE | marketed | Other | 1979-01-01 | ||
| Forane | ISOFLURANE | marketed | General Anesthetic [EPC] | 5-hydroxytryptamine receptor 2B | Neuroscience | 1979-01-01 |
| Aminoacetic Acid 1.5% In Plastic Container | GLYCINE | marketed | glycine | Olfactory receptor 51E2 | Metabolic | 1976-01-01 |
Therapeutic area mix
- Oncology · 6
- Metabolic · 4
- Neuroscience · 4
- Other · 3
- Infectious Disease · 3
- Immunology · 2
- Hematology · 1
- Gastroenterology · 1
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
- — Wydase · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Metro I.V. In Plastic Container · 8877792 · Formulation · US
- — Metro I.V. In Plastic Container · 7893097 · Formulation · US
- — Metro I.V. In Plastic Container · 8658678 · Method of Use · US
- — Prepopik · 8450338 · US
- — Prepopik · 8481083 · US
- — Renacidin · 8450338 · US
- — Renacidin · 8481083 · US
- — Metro I.V. In Plastic Container · 10238634 · Formulation · US
- — Metro I.V. In Plastic Container · 9198858 · Method of Use · US
- — Metro I.V. In Plastic Container · 10596155 · Formulation · US
- — Metro I.V. In Plastic Container · 8946276 · Method of Use · US
- — Renacidin · 11439610 · US
- — Renacidin · 11337989 · US
- — Renacidin · 10568855 · US
- — Renacidin · 10624879 · US
- — Prepopik · 10624879 · US
- — Prepopik · 11191753 · US
- — Renacidin · 11191753 · US
- — Prepopik · 9827231 · US
- — Renacidin · 9827231 · US
- — Cytoxan (Lyophilized) · 9662342 · Formulation · US
- — Cytoxan (Lyophilized) · 9662342 · Formulation · US
- — Cytoxan (Lyophilized) · 10849916 · Formulation · US
- — Cytoxan (Lyophilized) · 10849916 · Formulation · US
- — Cytoxan (Lyophilized) · 11382923 · Formulation · US
- — Cytoxan (Lyophilized) · 11382923 · Formulation · US
- — Cytoxan (Lyophilized) · 12329767 · Formulation · US
- — Cytoxan (Lyophilized) · 10993952 · Formulation · US
- — Cytoxan (Lyophilized) · 12329767 · Formulation · US
- — Cytoxan (Lyophilized) · 10993952 · Formulation · US
Competitive overlap (companies sharing drug classes)
- · 7 shared drug classes
- Pfizer Inc. · 3 shared drug classes
- Merck & Co. · 2 shared drug classes
- Baxter · 2 shared drug classes
- Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
- GSK · 2 shared drug classes
- Apotex · 1 shared drug class
- Alpharma Us Pharms · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Baxter International:
- Baxter International pipeline updates — RSS
- Baxter International pipeline updates — Atom
- Baxter International pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Baxter International — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/baxter. Accessed 2026-05-13.